Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party.

Duque-Afonso J, Finke J, Ferhat-Berland T, Galimard JE, Kinsella F, Richardson D, Stölzel F, Tholouli E, Besley C, Eder M, Nicholson E, Zeiser R, Bloor A, Crawley C, Clesham K, Byrne J, Medd P, Sala E, Pabst C, Vydra J, Wagner-Drouet EM, Gadisseur A, Spyridonidis A, Brissot E, Nagler A, Mohty M, Ciceri F

Open source

DOI: 10.1038/s41409-026-03016-7
Published: 2026 Sep 10
Container: Bone marrow transplantation
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41409-026-03016-7,
  title = {Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party.},
  author = {Duque-Afonso J and Finke J and Ferhat-Berland T and Galimard JE and Kinsella F and Richardson D and Stölzel F and Tholouli E and Besley C and Eder M and Nicholson E and Zeiser R and Bloor A and Crawley C and Clesham K and Byrne J and Medd P and Sala E and Pabst C and Vydra J and Wagner-Drouet EM and Gadisseur A and Spyridonidis A and Brissot E and Nagler A and Mohty M and Ciceri F},
  year = {2026},
  journal = {Bone marrow transplantation},
  doi = {10.1038/s41409-026-03016-7},
  url = {https://doi.org/10.1038/s41409-026-03016-7}
}

RIS

TY  - JOUR
TI  - Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party.
AU  - Duque-Afonso J
AU  - Finke J
AU  - Ferhat-Berland T
AU  - Galimard JE
AU  - Kinsella F
AU  - Richardson D
AU  - Stölzel F
AU  - Tholouli E
AU  - Besley C
AU  - Eder M
AU  - Nicholson E
AU  - Zeiser R
AU  - Bloor A
AU  - Crawley C
AU  - Clesham K
AU  - Byrne J
AU  - Medd P
AU  - Sala E
AU  - Pabst C
AU  - Vydra J
AU  - Wagner-Drouet EM
AU  - Gadisseur A
AU  - Spyridonidis A
AU  - Brissot E
AU  - Nagler A
AU  - Mohty M
AU  - Ciceri F
PY  - 2026
JO  - Bone marrow transplantation
DO  - 10.1038/s41409-026-03016-7
UR  - https://doi.org/10.1038/s41409-026-03016-7
ER  -

APA

J, D., J, F., T, F., JE, G., F, K., D, R., F, S., E, T., C, B., M, E., E, N., R, Z., A, B., C, C., K, C., J, B., P, M., E, S., C, P., J, V., EM, W., A, G., A, S., E, B., A, N., M, M., & F, C. (2026). Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party.. Bone marrow transplantation. https://doi.org/10.1038/s41409-026-03016-7

Source records

pubmed · retrieved 2026-09-26T00:56:23.006Z